Earnings Call · Q4 FY2023·2024-03-14

Q4 23EPS -4.17%·Rev n/aQ3 23EPS +9.09%·Rev n/aQ2 23EPS +18.52%·Rev n/aQ1 23EPS +29.27%·Rev n/a⚠ consensus missing

aTYR PHARMA INC ATYR

Ashlee Dunston — Investor Relations or Corporate Communications

Sanjay Shukla — President and Chief Executive Officer

Jill Broadfoot — Chief Financial Officer

+22.8%1d on move date+23.5% vs SPY3d+23.5%5d+24.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ATYR calls or request research access.

More ATYR calls Browse calls Request research access